Paris, France, [19 April 2018] – Pharmaleads, an emerging pharmaceutical company developing innovative non-opiate products for the management of acute and chronic severe pain, will present at BioTrinity 2018 in London on Tuesday, April 24th at 3.35pm.
Michel Wurm, VP Medical Affairs, will introduce Pharmaleads and its innovative compounds, PL265 and PL37, which protect enkephalins, the key elements of the body’s physiological pain modulation system, from degradation, thereby durably increasing their concentrations in the nervous system. The size of the chronic severe pain market is estimated at more than 200 million people in Europe and in the United States.
BioTrinity is Europe’s leading biopartnering and investment conference and the largest of its type in the UK. The conference, in its 12th year, draws attendees from approximately 30 countries and includes close to 120 life sciences investors, as well as industry leaders from global pharma.